Compare Cytokinetics Inc (CYTK) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard High Dividend Yield ETF — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Vanguard High Dividend Yield ETF trades at $160.26. Which is the better fit depends on your goals.
| CYTK | VYM | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $161.17 |
52-Week Low | $33.23 | $132.90 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
VYM trades at $160.86, down slightly by 0.12% today, with a bullish technical outlook supported by moving averages. The ETF maintains strong investor interest as a dividend income vehicle with $78.33 billion in assets and 618 holdings. Recent news highlights its role in retirement portfolios for tax-efficient income generation, though some articles question whether alternative funds offer better yields or performance.
The outlook remains positive for income-focused investors seeking broad diversification and low costs. Key risks include interest rate sensitivity and potential dividend sustainability during market downturns. Analyst sentiment favors VYM for long-term dividend growth despite current yield comparisons with competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
